SEC Form 4 · accession 0001628280-26-062701
CRESCENT BIOPHARMA, INC. · CBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua T Brumm
Officer — Chief Executive Officer · Director
Period of report
Sep 16, 2026
Accepted (ET)
Sep 18, 2026 · 4:02 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001253689
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Sep 16, 2026 | S | 1,610 | $17.90 | D | 279,602 | D | |
| Ordinary SharesF1,F2 | Sep 18, 2026 | S | 7,837 | $16.71 | D | 271,765 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 28, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
- F2The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17 on September 16, 2026 and from $16.15 to $17.23 on September 18, 2026, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
Remarks
Exhibit 24 - Power of Attorney